Zeit	Session	Beitrag	Autoren	Institution	Die Präsentation
Sunday, 9:30 a.m. - 11:30 a.m.	002. New Antimicrobial Agents	12. BAY 41-4109 : a Novel Anti-HBV Agent	ARNOLD PAESSENS1, ERWIN GRAEF1, KARL DERES1, ULRICH NIEWOEHNER1, JUERGEN STOLTEFUSS1, FRANK KROETLINGER1, BERND HERBOLD1, RAINER JAEGER1, ARMIN KERN1, BERND BECKERMANN1, DIETER HAEBICH1, HELGA RUEBSAMEN-WAIGMANN1, RALF N. A. MASANTSCHEK1, DIANA KOLETZKI1, WILLIAM S. MASON2, CLAUS H. SCHROEDER3, KARL-HEINZ SCHLEMMER1, ELKE HARTMANN1, OLAF WEBER1, SIEGFRIED GOLDMANN1, STEFAN WOHLFEIL1;	1Bayer AG, Wuppertal, Germany, 2Fox Chase Cancer Center, Philadelphia, PA, 3German Cancer Research Center, Heidelberg, Germany.
Sunday, 9:30 a.m. - 11:00 a.m.	004. Human Pharmacokinetics and Drug-Drug Interactions of Antifungals	31. Fluconazole in Anuric Patients Undergoing Continuous-Veno-Venous-Hemodialysis (CVVHD): Pharmacokinetics and Dosage Simulation	S. C. MUELLER1, J. MAJCHER-PESZYNSKA1, R. G. MUNDKOWSKI1, H. HICKSTEIN2, B. DREWELOW1;	1Clinical Pharmacology, University of Rostock, Rostock, Germany, 2Nephrology, University of Rostock, Rostock, Germany.
Sunday, 9:30 a.m. - 11:00 a.m.	005. Pharmacokinetics of Quinolones in Children and Adults	40. Influence of Charcoal on the Gastro-Intestinal Circulation of Moxifloxacin (MFX) in Healthy Male Volunteers	HEINO H. STASS1, D. KUBITZA2, J.-G. MOELLER2;	1Pharma Research Center, Bayer AG, Wuppertal, Germany, 2Pharma research center, Bayer AG, Wuppertal, Germany.
Sunday, 9:30 a.m. - 11:00 a.m.	007. Surveillance of Antimicrobial Resistance	71. Longitudinal Change of Antibiotic Susceptibility of Pseudomonas aeruginosa in Cystic Fibrosis	B. PRZYKLENK1, A. BAUERNFEIND2;	1University Children's Hospital, München, Germany, 2MICOER-Institute, München, Germany.
Sunday, 9:30 a.m. - 11:00 a.m.	008. Pneumococcal Vaccines	85. Immunogenicity, Reactogenicity and Safety of a 7-Valent Pneumococcal Conjugate Vaccine (7VPnC) Given Concomitantly with a 5-Component DTaP-IPV-Hib Vaccine	H. SCHMITT1, J. FABER1, I. BARTELS2, B. SCHMOELE-THOMA3, N. AHLERS3;	1Univ.-Children's Hosp., Mainz, Germany, 2Univ.-Children's Hosp., Erlangen, Germany, 3Wyeth Pharma GmbH, Muenster, Germany.
Sunday, 11:00 a.m. - 12:30 noon	013. Quinolone Resistance	146. Selection of Quinolone-Resistance by Structurally Unrelated Compounds	A. DALHOFF1, A. HEISIG2, P. HEISIG2;	1Bayer AG, Wuppertal, Germany, 2Univ. Hamburg, Hamburg, Germany.
Sunday, 11:00 a.m. - 12:30 noon	014. Resistance Gene Clusters	157. Identification of an Antibiotic Resistance Gene Cluster in Pasteurella and Mannheimia	C. KEHRENBERG, S. SCHWARZ;	Inst. Animal Sci. and Animal Behaviour, Celle, Germany.
Sunday, 11:00 a.m. - 12:30 noon	015. Resistance to Inhibitors of Transcription and Translation	164. Aminoglycoside-Streptothricin Resistance Genes in Enterococcus faecium of Different Origins	G. WERNER, W. WITTE;	Robert Koch Inst., Wernigerode Branch, Wernigerode, Germany.
Sunday, 11:00 a.m. - 12:30 noon	017. Detection of ESBLs and Other ß-Lactamases	184. The Importance of Extended-Spectrum ß-Lactamases (ESBL) Screening Tests in Rapid Automated Antimicrobial Susceptibility Testing (AST)	R. GROSS1, J. HOERLING1, U. EIGNER2, ANNE MARIE FAHR2;	1University of Muenster, Muenster, Germany, 2Laboratory Group, Heidelberg, Germany.
Sunday, 11:00 a.m. - 12:30 noon	018. Evaluation of Susceptibility Testing Methods	192. Rapid Detection of Methicillin resistant Staphylococcus aureus Isolates by an Nucleic Acid Based Hybridisation Assay	S. SINGER, M. WEIZENEGGER, M. HENGSTLER, J. BARTEL, A. FAHR;	Laboratory Group, Dept. of Microbiology, Heidelberg, Germany.
Sunday, 11:00 a.m. - 12:30 noon	021. Fungal Epidemiology	259. Molecular Typing of Scedosporium apiospermum	PETER M. RATH;	Universität Essen, Institut für Medizinische Mikrobiologie, Essen, Germany.
Sunday, 11:00 a.m. - 12:30 noon	021. Fungal Epidemiology	272. The Role of Candida albicans Secreted Aspartic Proteinases in Antibiotic-Associated Diarrhea	R. KRAUSE1, E. SCHWAB1, F. DAXBÖCK1, G. J. KREJS1, E. C. REISINGER2, C. WENISCH1;	1Division of Infectious Diseases, Graz, Austria, 2Division of Infectious Diseases, Rostock, Germany.
Sunday, 1:30 p.m. - 3:00 p.m.	032. In Vitro Synergy Studies	335. In Vitro Activity of the Beta-Lactamase Inhibitors Clavulanic Acid (CLA), Sulbactam (SUL), and Tazobactam (TAZ) Alone or in Combination with Beta-lactams against Epidemiologically Characterized Multi-Drug Resistant Acinetobacter baumannii Strains	H. SEIFERT, D. STEFANIK, H. WISPLINGHOFF;	Institute of Medical Microbiology and Hygiene, Univ. of Cologne, Cologne, Germany.
Sunday, 1:30 p.m. - 3:00 p.m.	034. Novel ß-Lactams and ß-Lactamase Inhibitors	377. Mechanism of Action of New Siderophore Acylaminopenicillins	U. MÖLLMANN1, L. HEINISCH1, D. ANKEL-FUCHS2, T. KÖHLER3;	1Hans-Knöll-Inst., Jena, Germany, 2Grünenthal GmbH, Aachen, Germany, 3University of Geneva, Geneva, Switzerland.
Sunday, 1:30 p.m. - 3:00 p.m.	034. Novel ß-Lactams and ß-Lactamase Inhibitors	378. Antibacterial Activity of New Siderophore Acylaminopenicillins	U. MÖLLMANN1, L. HEINISCH1, A. BAUERNFEIND2, I. SCHNEIDER2, F. J. SCHMITZ3, D. ANKEL-FUCHS4;	1Hans-Knöll-Inst., Jena, Germany, 2MICOER Inst., Munich, Germany, 3University of Düsseldorf, Düsseldorf, Germany, 4Grünenthal GmbH, Aachen, Germany.
Sunday, 1:30 p.m. - 3:00 p.m.	034. Novel ß-Lactams and ß-Lactamase Inhibitors	382. AM-112, a Novel Oxapenem β-Lactamase Inhibitor with Unexpected Synergistic Activity with Ceftazidime against Enterococci, Including Some Vancomycin-Resistant Isolates	CONOR E. JAMIESON1, P. A. LAMBERT1, R. HAKENBECK2, I. N. SIMPSON3;	1Aston University, Birmingham, United Kingdom, 2Universitat Kaiserslautern, Kaiserslautern, Germany, 3Micron Research, Cambridge, United Kingdom.
Sunday, 1:30 p.m. - 3:00 p.m.	035. Pharmacoeconomics and Antibiotic Utilization	389. Influence of an Infectious Disease Consulting Service on Quality and Costs of Antibiotic Prescriptions at a University Hospital	SEBASTIAN W. LEMMEN, A. BAUER, S. KOTTERIK, H. NGYEN, C. BREUER, R. LÜTTICKEN, H. HEINTZ;	Univ. Hosp. Aachen, Aachen, Germany.
Sunday, 2:00 p.m. - 4:30 p.m.	044. Hepatitis Viruses	465. Detection of Hepatitis G Virus RNA and Antibodies to HGV in Hemodialysis Children	PAUL SCHNITZLER1, JULIA BERINGER1, MARKUS DASCHNER2, MAGDALENA GEISS1, HEIKE VON BAUM1;	1Institute of Hygiene, Heidelberg, Germany, 2Dept. of Pediatrics, Heidelberg, Germany.
Sunday, 3:00 p.m. - 4:30 p.m.	052. Novel Quinolones II	557. The In Vitro Activity of Non-Fluorinated Quinolones against Molecularly Characterized, Quinolone-Susceptible and -Resistant Isolates of Staphylococcus aureus and Streptococcus pneumoniae	M. E. JONES1, J. A. KARLOWSKY2, R. S. BLOSSER2, I. A. CRITCHLEY2, E. KARGINOVA2, F. J. SCHMITZ3, C. THORNSBERRY2, D. F. SAHM2;	1Focus Technologies/MRL, Hilversum, Netherlands, 2Focus Technologies/MRL, Herndon, VA, 3University Hospital, Dusseldorf, Germany.
Monday, 8:30 a.m. - 11:00 a.m.	069. The Consequences of Antibiotic Resistance	652. Attached Staphylococcus epidermidis Has Reduced Susceptibility against Quinolones Independent from Biofilm Formation	JOHANNES K. M. KNOBLOCH, H. VON OSTEN, D. MACK;	Institute of Medical Microbiology and Immunology, Hamburg, Germany.
Monday, 8:30 a.m. - 11:00 a.m.	070. Respiratory Viruses	663. Effectiveness of Oral Oseltamivir in Preventing Spread of Influenza-Like Illness in Households with Proven Influenza	R. B. BELSHE1, F. HAYDEN2, O. CAREWICZ3, R. LANNO4, C. MARTIN5, C. HUGHES6, P. WARD6;	1Saint Louis University, St Louis, MO, 2University of Virginia, Charlottesville, VA, 3General Practice, Dossenheim, Germany, 4Merealahe Family Doctors Practice, Tallinn, Estonia, 5Roche Global Development, Basel, Switzerland, 6Roche Global Development, Welwyn, United Kingdom.
Monday, 8:30 a.m. - 11:00 a.m.	071. HIV Session I	671. Switch to Trizivir Versus Continued HAART Provides Equivalent HIV-1 RNA Suppression at 48 weeks (TRIZAL - AZL30002)	C. KATLAMA1, S. FENSKE2, B. GAZZARD3, A. LAZZARIN4, L. BEAUVAIS5;	1Hôpital Pitié-Salpêtrière, Paris, France, 2HIV-Schwerpunktpraxis, Hamburg, Germany, 3Chelsea and Westminster Hosp., London, United Kingdom, 4San Raffaele Scientific Institute, Milan, Italy, 5GlaxoSmithKline, Marly le Roi, France.
Monday, 8:30 a.m. - 11:00 a.m.	072. Clinical Mycology	681. Itraconazole for Antifungal Prophylaxis in Neutropenic Patients: a Meta-Analysis of 2181 Patients	A. GLASMACHER1, C. HAHN1, E. MOLITOR2, G. MARKLEIN2, I. SCHMIDT-WOLF1;	1Dpt. of Internal Medicine I, Univ. of Bonn, Bonn, Germany, 2Inst. of Med. Microbiology and Immunology, Univ. of Bonn, Bonn, Germany.
Monday, 9:30 a.m. - 11:00 a.m.	073. Antimicrobial Resistance of Respiratory Pathogens	685. Prevalence of Antibiotic Resistance among European Respiratory Tract Pathogens (1999/2000)	D. FELMINGHAM1, R. R. REINERT2;	1GR Micro, London, United Kingdom, 2Natl. Reference Ctr. for Streptococci, Aachen, Germany.
Monday, 9:30 a.m. - 11:00 a.m.	073. Antimicrobial Resistance of Respiratory Pathogens	692. Worldwide Surveillance of Antibiotic Resistance among Clinical Isolates of Streptococcus pneumoniae and Streptococcus pyogenes during 1999/2000	R. R. REINERT1, D. J. HOBAN2, D. FELMINGHAM3, J. PLUIM4;	1Natl. Reference Ctr. for Streptococci, Aachen, Germany, 2Health Sciences Ctr., Winnipeg, Canada, 3GR Micro, London, United Kingdom, 4Aventis Pharma, Bridgewater, NJ.
Monday, 9:30 a.m. - 11:00 a.m.	073. Antimicrobial Resistance of Respiratory Pathogens	693. Antibiotic Resistance of Streptococcus pyogenes and Streptococcus pneumoniae Strains Isolated from RTI of Outpatients in Germany, 2000-2001	R. R. REINERT, R. LUETTICKEN, C. BRIEFS, N. NEUBERGER, M. LEMPERLE, A. AL-LAHHAM;	National Reference Center for Streptococci, Aachen, Germany.
Monday, 9:30 a.m. - 11:00 a.m.	079. Infections in Neutropenic Patients	775. Three-Armed Multicenter Randomized Study on the Empiric Treatment of Neutropenic Fever in a High Risk Patient Population (PEG Study III)	OLIVER A. CORNELY1, D. REICHERT2, D. BUCHHEIDT3, G. MASCHMEYER4, M. WILHELM5, X. SCHIEL6, B. GLAß7, G. FÄTKENHEUER1, H. LINK8, M. HELMERKING9, D. ADAM10, W. HIDDEMANN6, FOR THE PAUL-EHRLICH-GESELLSCHAFT (PEG);	1Univ Hosp, Koeln, Germany, 2Städtische Kliniken, Oldenburg, Germany, 3Univ Hosp, Mannheim, Germany, 4Charité, Berlin, Germany, 5Univ Hosp, Würzburg, Germany, 6Univ Hosp, Med Clin III, Munich, Germany, 7Univ Hosp, Kiel, Germany, 8Westpfalz-Klinikum, Kaiserslautern, Germany, 9Algora CRO, Munich, Germany, 10von Haunersches Kinderspital, Univ Munich, Munich, Germany.
Monday, 9:30 a.m. - 11:00 a.m.	079. Infections in Neutropenic Patients	779. Reduction of Central Venous Catheter-Related Infection (CRI) in Cancer Patients with Severe Neutropenia: A Prospective Controlled Randomized Trial Using a Chlorhexidine and Silver-Sulfadiazine Impregnated Central Venous Line (CH-SS)	S. ZENZ1, H. RUSCHULTE1, A. OSTHAUS1, J. HEINE1, B. JUETTNER1, G. HEIL2, K. JAEGER1, M. KARTHAUS3;	1Dept. Anesthesiology Hannover Med. Sch., Hannover, Germany, 2Dept. Hematology Hannover Med. Sch., Hannover, Germany, 3Ev. Johannes Krankenhaus, Bielefeld, Germany.
Monday, 11:00 a.m. - 12:30 noon	080. Endocarditis and Vascular Infections	782. Expression of Staphylococcus aureus Fibronectin-Binding Protein A (FnBPA) Mediates Bacterial Internalization by Endothelial Cells In Vitro and in Rats with Experimental Endocarditis (EE)	YOK-AI QUE1, J-A HAEFLIGER1, P. FRANCOIS2, S. PIU1, B. SINHA3, J-M ENTENZA1, J. VOUILLAMOZ1, M. HERRMANN3, P. VAUDAUX2, P. MOREILLON1;	1CHUV, Lausanne, Switzerland, 2HCUGE, Geneva, Switzerland, 3Medical Microbiology, Muenster, Germany.
Monday, 11:00 a.m. - 12:30 noon	081. Carbapenems In Vitro	793. In Vitro Activity of Faropenem against Pediatric Isolates	D. ADAM;	Klinikum Innenstadt der LMU, Munich, Germany.
Monday, 11:00 a.m. - 12:30 noon	081. Carbapenems In Vitro	795. In Vitro Activity of Faropenem (FAR) against Genetically Characterized Isolates of Moraxella catarrhalis and Streptococcus pneumoniae	F. J. SCHMITZ1, M. BOOS1, S. MAYER1, J. VERHOEF2, D. MILATOVIC2, A. C. FLUIT2;	1Univ. Hosp. Dusseldorf, Dusseldorf, Germany, 2Univ. Hosp Utrecht, Utrecht, Netherlands Antilles.
Monday, 11:00 a.m. - 12:30 noon	081. Carbapenems In Vitro	798. Anti-Staphylococcal Activity of Faropenem	C. VON EIFF, S. SCHEPERS, G. PETERS;	Univ. Münster Hosp. and Clinics, Munster, Germany.
Monday, 11:00 a.m. - 12:30 noon	083. Clinical Mycology	833. Systemic Fungal Infections in Preterm and Term Infants in Germany	A. H. GROLL1, S. ELSTNER2, R. SCHLOESSER3, FRANK-MICHAEL MÜLLER2, R. ROOS4;	1Pediatric Oncology Branch, NCI, Bethesda, MD, 2Dept. of Pediatrics, Würzburg, Germany, 3Dept. of Pediatrics, Frankfurt, Germany, 4Children's Hospital Harlaching, München, Germany.
Monday, 11:00 a.m. - 12:30 noon	084. Fungal Diagnosis	839. Development and Evaluation of the Nuclisens Basic Kit NASBA for the Detection of RNA from Yeast Frequently Resistant to Antifungal Drugs	JUERGEN H. LOEFFLER, C. DORN, H. HEBART, P. COX, S. MAGGA, H. EINSELE;	Medizinische Klinik, Tuebingen, Germany.
Monday, 11:00 a.m. - 12:30 noon	084. Fungal Diagnosis	840. Specific Detection of Genomic Fungal DNA from Clinically Relevant Yeast and Moulds Using the Pyrosequencing Technology	JUERGEN H. LOEFFLER1, B. GHARIZADEH2, E. NORBERG3, S. GALAL3, L. KLINGSPOR3, J. TOLLEMAR3, H. EINSELE1, P. NYREN2;	1Medizinische Klinik, Tuebingen, Germany, 2Royal Institute of Technology, Stockholm, Sweden, 3Huddinge University Hospital, Huddinge, Sweden.
Monday, 11:00 a.m. - 12:30 noon	085. Community-Acquired Pneumonia	863. Clinical and Outcomes Assessment of the Management of Community-Acquired Pneumonia (CAP): a Comparison of Moxifloxacin to Standard First-Line Oral Monotherapy or Combination Regimen	G. HÖFFKEN1, P. A. CORRIS2, J. S. MUIR3, P. P. SAGNIER4, I. DUPRAT-LOMON44, R. KUBIN5, A. TORRES6;	1Universitätsklinikum, Dresden, Germany, 2Freeman Hospital, Newcastle, United Kingdom, 3Hôpital BoisGuillaume, Rouen, France, 4Bayer PLC, Slough, United Kingdom, 5Bayer AG, Wuppertal, Germany, 6Institute Clinic de Malalties Respiratories, Barcelona, Spain.
Monday, 11:00 a.m. - 12:30 noon	085. Community-Acquired Pneumonia	864. Superior Outcomes with Moxifloxacin IV/PO Monotherapy Compared to IV/PO Amoxicillin/Clavulanate ± Clarithromycin in the Treatment of Community-Acquired Pneumonia (CAP)	M. DRUMMOND1, R. FINCH2, I. DUPRAT-LOMON3, P. P. SAGNIER3, O. COLLINS4, R. KUBIN5;	1University of York, York, United Kingdom, 2The City Hospital, Nottingham, United Kingdom, 3Bayer plc, Slough, United Kingdom, 4Bayer plc, Newbury, United Kingdom, 5Bayer AG, Wuppertal, Germany.
Monday, 1:30 p.m. - 3:00 p.m.	097. Human Pharmacokinetics of Antimicrobials	940. Effect of Multiple Dose Treatments with Faropenem Daloxate in Comparison to Amoxicillin / Clavulanic Acid on the Normal Fecal and Oropharyngeal Flora of Healthy Subjects	J. NAGELSCHMITZ1, M. KOCH2, W. R. HEIZMANN2, C. KRASEMANN1, B. U. VOIGHT1, J. KUHLMANN1, G. WENSING1;	1Bayer AG, Wuppertal, Germany, 2Labor Wagner & Partner, Gottingen, Germany.
Monday, 1:30 p.m. - 3:00 p.m.	097. Human Pharmacokinetics of Antimicrobials	943. Absorption of Faropenem Daloxate Delivered Locally to Different Sites of the Gastrointestinal Tract (GIT) by an Enterion Capsule	B. VOITH1, I. WILDING2, A. WRAY2, A. CONNOR2, U. VOIGT1, J. NAGELSCHMITZ1, J. KUHLMANN1;	1Inst. of Clin. Pharmacology, Bayer AG, Wuppertal, Germany, 2Pharmaceutical Profiles, Nottingham, United Kingdom.
Monday, 1:30 p.m. - 3:00 p.m.	097. Human Pharmacokinetics of Antimicrobials	944. No Evidence of Active Metabolites of Faropenem	A. SCHMIDT, B. VOITH, A. DALHOFF;	Bayer AG, Wuppertal, Germany.
Monday, 1:30 p.m. - 3:00 p.m.	097. Human Pharmacokinetics of Antimicrobials	946. Tissue Penetration of Cefditoren (CEE) into Bronchial Mucosa (BM) and Epithelial Lining Fluid (ELF) in Patients Undergoing Fiberoptic Bronchoscopy	M. KINZIG-SCHIPPERS1, M. HINDER2, K. GÖHLER2, U. LOOS3, F. VOGEL4, F. SORGEL1;	1IBMP, Nürnberg, Germany, 2Grünenthal GmbH, Aachen, Germany, 3Knappschaft Hosp., Recklinghausen, Germany, 4Hosp. Internal Medicine, Hofheim a. T., Germany.
Monday, 1:30 p.m. - 3:00 p.m.	098. Microbial Virulence Factors	953. Importance of Sortase in a Staphylococcus aureus Foreign Body Infection Model	M. E. RUPP1, P. D. FEY1, W. GILES1, S. H. HINRICHS1, G. THUMM2, F. GOTZ2;	1Univ of Nebraska Med Ctr, Omaha, NE, 2Univ of Tubingen, Tubingen, Germany.
Monday, 1:30 p.m. - 3:00 p.m.	098. Microbial Virulence Factors	969. Electroporation of DNA Sequences from the Pathogenicity Locus (PaLoc) of Toxigenic Clostridium difficile into a Nontoxigenic Strain	G. ACKERMANN1,2, Y. J. TANG1, J. P. HENDERSON1, A. C. RODLOFF2, J. SILVA JR.1, S. H. COHEN1;	1University of California, Davis, Sacramento, CA, 2University of Leipzig, Leipzig, Germany.
Monday, 1:30 p.m. - 3:00 p.m.	098. Microbial Virulence Factors	970. One -Step Cloning and Expression of Clostridium difficile Toxin B Gene (tcdB)	Y. J. TANG1, G. ACKERMANN1,2, J. P. HENDERSON1, J. SILVA, JR.1, S. H. COHEN1;	1University of California, Davis, Sacramento, CA, 2University of Leipzig, Leipzig, Germany.
Monday, 1:30 p.m. - 3:00 p.m.	100. Ketolide Susceptibility Studies	1001. Comparative In Vitro Activity of ABT-773 and Two Macrolides against Staphylococci	C. VON EIFF, G. PETERS;	Inst. of Med. Microbiol., Univ. of Münster, Hosp. and Clin., Münster, Germany.
Monday, 1:30 p.m. - 3:00 p.m.	100. Ketolide Susceptibility Studies	1007. In Vitro Activity of ABT-773 and Six Other Antibacterial Agents against Recent Community-Acquired Respiratory Tract Isolates: a German Multicenter Study	S. BAGEL, J. BRAUERS, M. KRESKEN;	Antiinfectives Intelligence, Bonn, Germany.
Monday, 2:00 p.m. - 4:30 p.m.	105. Multiple Pathways to Glycopeptide Resistance in Staphylococci	1069. Role of Teichoic Acid Structure In Susceptibility to Glycopeptide Antibiotics	ANDREAS PESCHEL;	Univ. Tuebingen, Tuebingen, Germany.
Monday, 3:00 p.m. - 4:30 p.m.	121. Infection Control and Hospital Epidemiology	1208. Plasma Sterilization: Efficacy of the New STERRAD 200 Tested in the Hospital Setting	A. F. WIDMER1, J. OKPARA2, R. FREI1, B. JAUSSI1, M. BORNEFF2;	1University Hospitals, Basel, Switzerland, 2Martin Luther University, Halle, Germany.
Monday, 2:00 p.m. - 4:30 p.m.	112. Sepsis	1107. Mutations of Toll-Like Receptor (TLR) 4 are Associated withIncidence and Severity of Sepsis in Critically Ill Patients	R. R. SCHUMANN1, E. LORENZ2, E. LATZ3, N. LIMMER1, P. M. SCHLAG3, D. A. SCHWARTZ2;	1Inst. f. Microbiology, Charité Medical Center, Berlin, Germany, 2Duke University Medical Center, Durham, NC, 3Department of Surgery and Surgical Oncology, Robert-Rössle-Klinik, Charité Medical Center, Berlin, Germany.
Monday, 3:00 p.m. - 4:30 p.m.	123. Nosocomial Infections II: Clostridium difficile	1234. Association between Antecedent Use of Fluoroquinolones and Resistance to Moxifloxacin (MXF) in Clostridium difficile	GRIT ACKERMANN1,2, Y. J. TANG1, R. SCHAUMANN2, J. P. HENDERSON1, A. C. RODLOFF2, J. SILVA, JR.1, S. H. COHEN1;	1University of California, Davis, Sacramento, CA, 2University of Leipzig, Leipzig, Germany.
Monday, 3:00 p.m. - 4:30 p.m.	125. Nosocomial Infections in Immunosuppressed Hosts	1251. Oral Flora and Mucositis Grade During Myeloablative Chemotherapy	H. LOEVENICH1, C. KEULERTZ1, H. SCHUETT-GEROWITT2, U. BETHE1, D. SOEHNGEN1, D. WALDSCHMIDT1, O. A. CORNELY1;	1University of Cologne, Dept. of Internal Med., Cologne, Germany, 2University of Cologne, Inst. of Microbiol., Cologne, Germany.
Tuesday, 8:30 a.m. - 11:00 a.m.	141. Surveillance and Mechanisms of Macrolide Resistance	1320. The Recently Identified Gene, msrC, Is Not Equally Distributed among Enterococcus faecium of Different Ecological Origins	G. WERNER, W. WITTE;	Robert Koch Inst., Wernigerode Branch, Wernigerode, Germany.
Tuesday, 8:30 a.m. - 11:00 a.m.	143. Hand Hygiene at Last?	1338. Limited Efficacy of Alcohol-Based Hand Gels for Hand Antisepsis	D. PITTET1, P. RUDOLPH2, A. KRAMER2;	1University of Geneva Hospitals, Geneva, Switzerland, 2Univ. of Greifswald, Greifswald, Germany.
Tuesday, 9:30 a.m. - 11:00 a.m.	149. Linezolid In Vitro	1423. In Vitro Activity of Linezolid, Eperezolid, Quinupristin/Dalfopristin, and the new Glycopeptide LY 333328 against Enterococci Recovered from Intensive Care Units and Hematology-Oncology Wards of a German University Hospital	FRIEDRICH B. SPENCKER, K. GRESENS, A. C. RODLOFF;	Institute of Medical Microbiology and Epidemiology of Infection, Univ. of Leipzig, Leipzig, Germany.
Tuesday, 9:30 a.m. - 11:00 a.m.	150. Nosocomial Bloodstream Infections	1434. Incidence of Central Venous Catheter(CVC)-Associated Bloodstream Infections in Patients with Febrile Neutropenia Treated for Acute Leukemia (AL)	M. KARTHAUS1, T. DOELLMANN2, S. WEBER3, G. HEIL2, A. GANSER2;	1Ev. Johannes Krankenhaus, Bielefeld, Germany, 2Dept. Hematology, Hannover Med. Sch., Hannover, Germany, 3Dept. Microbiology, Hannover Med. Sch., Hannover, Germany.
Tuesday, 9:30 a.m. - 11:00 a.m.	153. Nosocomial Infections VI: Surgical Site and Prosthetic Device Infections	1454. Deep Sternal Wound Infection Following Cardiac Surgery - Epidemiology and Treatment	D. V. SCHMITT1, M. C. CLAROS2, J. F. GUMMERT1, A. C. RODLOFF2, F. W. MOHR1;	1Department of Cardiac Surgery, University of Leipzig, Leipzig, Germany, 2Institute of Medical Microbiology, University of Leipzig, Leipzig, Germany.
Tuesday, 9:30 a.m. - 11:00 a.m.	154. Utilization of Antibiotics in the Intensive Care Unit	1465. Transmission of Nosocomial Pathogens in Five Intensive Care Units (ICU) in a German University Hospital	K. BECK-BEILECKE, P. GASTMEIER, H. RÜDEN, MEMBERS OF SIR3 RESEARCH GROUP;	Inst. of Hygiene, Free Univ./ Dept. of Hospital Hygiene, Charité, Berlin, Germany.
Tuesday, 11:00 a.m. - 12:30 noon	157. ß-Lactamases: Bla, Bla, Bla...	1500. Aeromonas veronii bv. Sobria Beta-Lactamase Induction isLinked to Disruption of Cell-Wall Metabolism	M. B. AVISON1, K. WESTPHAL2, P. NIUMSUP1, T. R. WALSH1, A. P. MACGOWAN1, B. WIEDEMANN2, P. M. BENNETT1;	1University of Bristol, Bristol, United Kingdom, 2University of Bonn, Bonn, Germany.
Tuesday, 11:00 a.m. - 12:30 noon	160. Pediatric Infectious Disease II	1539. A Prospective Randomized Trial Comparing the Efficacy and Safety of Piperacillin/Tazobactam Versus Piperacillin/Tazobactam Plus Netilmicin in the Treatment of Febrile Neutropenia in Allogeneic Stem Cell Recipients	MICHAEL G. KIEHL, M. BISCHOFF, N. BASARA, S. GUENZELMANN, A. A. FAUSER;	Clinic of Bone Marrow Transplantation and Hematology/Oncology, Idar-Oberstein, Germany.
Tuesday, 11:00 a.m. - 12:30 noon	161. Vaccine Trials	1560. Cellular Immune Response to Varicella in Healthy Subjects 12 to 22 Months Old Receiving either a Combined Measles-Mumps-Rubella-Varicella Vaccine or Separate Measles-Mumps-Rubella and Varicella Vaccines	F. ZEPP1, C. U. MEYER1, P. HABERMEHL1, M. KOUTSOUKOS2, J. M. STEENS2, F. BECKERS2;	1Johannes Gutenberg Universitat, Mainz, Germany, 2GlaxoSmithKline, Rixensart, Belgium.
Tuesday, 11:00 a.m. - 12:30 noon	164. Clinical Candidiasis and Aspergillosis	1624. A Double-Blind Study of Fluconazole Oral Suspension vs.Capsules in the Treatment of Oropharyngeal Candidiasis in HIV-Patients	M. EICHEL1, C. SCHNEIDER2, G. JUST-NUEBLING2;	1University Hospital, Frankfurt/Main, Germany, 2university hospital, Frankfurt/Main, Germany.
Tuesday, 12:00 noon - 1:50 p.m.	164b. Viruses, Fungi and Bacterial Pathogenesis	LB-14. AXD455 – A Novel Inhibitor of Antiretroviral Drug-Resistant HIV by Pharmacological Interference With Nuclear Export of Viral mRNA.	D. Bevec1, i. HAUBER2, f. KRÄTZER1, c. WALLASCH1, f. HORN2, h. WALTER2, t. HARRER2, j. HAUBER2, u. ELBEN1;	1Axxima Pharmaceuticals AG, Martinsried, GERMANY, 2Univ. Erlangen-Nürnberg, Erlangen, GERMANY.
Tuesday, 1:30 p.m. - 3:00 p.m.	171. Animal Models	1662. Effects of BMS 284,756, Ofloxacin and Ciprofloxacin on the Ultrastructure of Achilles Tendon in Juvenile Rats	MEHDI SHAKIBAEI1, E. M. KAPPEL2, S. FASSHEBER2, I. BAUMANN-WILSCHKE2, R. STAHLMANN2;	1Institut of Anatomy, Berlin, Germany, 2Institute of Clinical Pharmacology and Toxicology, Berlin, Germany.
Tuesday, 1:30 p.m. - 3:00 p.m.	172. Novel Antivirals	1664. BAY 41-4109: A Novel Non-Nucleosidic and Highly Potent Inhibitor of Human Hepatitis B Virus. Part 1: Synthesis and Structure Activity Relationship (SAR)	SIEGFRIED GOLDMANN, J. STOLTEFUSS, U. NIEWOEHNER, T. KRAEMER, E. GRAEF, K. DERES, R. N. A. MASANTSCHEK, O. WEBER, D. KOLETZKI, A. PAESSENS;	Bayer AG, Wuppertal, Germany.
Tuesday, 1:30 p.m. - 3:00 p.m.	172. Novel Antivirals	1665. BAY 41-4109: A Novel Non-Nucleosidic and Highly Potent Inhibitor of Human Hepatitis B Virus (HBV). Part 2: In Vitro Profile	A. PAESSENS1, E. GRAEF2, K. DERES2, S. GOLDMANN2, U. NIEWOEHNER2, J. STOLTEFUSS2, D. HAEBICH2, H. RUEBSAMEN-WAIGMANN2, D. KOLETZKI2, R.N.A. MASANTSCHEK2, W.S. MASON3, C.H. SCHROEDER4, O. WEBER2;	1Bayer AG, Wuppertal, Germany, 2BAYER AG, Wuppertal, Germany, 3Fox Chase Center, Philadelphia, PA, 4German Cancer Research Center, Heidelberg, Germany.
Tuesday, 1:30 p.m. - 3:00 p.m.	172. Novel Antivirals	1666. BAY 41-4109: A Novel Non-Nucleosidic and Highly Potent Inhibitor of Human Hepatitis B Virus. Part 3: In Vivo Profile	OLAF WEBER1, K.-H. SCHLEMMER2, E. GRAEF2, K. DERES2, S. GOLDMANN2, U. NIEWOEHNER2, J. STOLTEFUSS2, D. HAEBICH2, E. HARTMANN2, H. RUEBSAMEN-WAIGMANN2, A. PAESSENS2;	1Bayer AG, West Haven, CT, 2Bayer AG, Wuppertal, Germany.
Tuesday, 1:30 p.m. - 3:00 p.m.	172. Novel Antivirals	1667. BAY 41-4109: a Novel Non-Nucleosidic and Highly Potent Inhibitor of Human Hepatitis B Virus Induces HBV Core Protein Depletion: Part 4	K. DERES1, C. H. SCHROEDER2, U. PLEISS3, E. GRAEF3, S. GOLDMANN3, U. NIEWOEHNER3, J. STOLTEFUSS3, O. WEBER3, D. KOLETZKI3, R. MASANTSCHEK3, A. PAESSENS3, D. HAEBICH3, H. RUEBSAMEN-WAIGMANN3;	1Bayer AG, Wuppertal, Germany, 2DKFZ, Heidelberg, Germany, 3BAYER AG, Wuppertal, Germany.
Tuesday, 1:30 p.m. - 3:00 p.m.	175. Antiretroviral Agents: Adherence, Pharmacokinetics, and Pharmacodynamics	1741. Longterm Pharmacokinetics (PK) of Amprenavir (APV) in Combination with Ritonavir (RTV) or Delavirdine (DLV) in HIV-Infected Children	UWE H. P. WINTERGERST, M. KUROWSKI, C. ENGELHORN, F. HOFFMANN, S. URSCHEL, G. NOTHEIS, B. H. BELOHRADSKY;	University Children's Hospital, Munich, Germany.
Tuesday, 1:30 p.m. - 3:00 p.m.	176. Antiretroviral Resistance	1745. Evaluation of an Open Expert-Based Genotype Interpretation Program: RetroGram	A.M BEEN-TIKTAK1, K. KORN2, W. KEULEN1,3, E. SCHWINGEL2, H. WALTER2, B. SCHMIDT2, H. STIRNADEL4, J. SCHAPIRO5, C. BOUCHER3;	1Virology Networks, Utrecht, Netherlands, 2Institute of Clinical and Molecular Virology, University of Erlangen-Nurnberg, Erlangen, Germany, 3University Medical Center, Utrecht, Netherlands, 4Roche Discovery, Welwyn, United Kingdom, 5Stanford University, Stanford, CA.
Tuesday, 1:30 p.m. - 3:00 p.m.	176. Antiretroviral Resistance	1758. M184V Independent Resistance to Abacavir Detected by HIV Phenotypic Assay	THOMAS E. O. FENNER1, N. WIESE1, H. MUELLER1, U. SCHMITZ2, H. PETERSEN3;	1Laboratory Dres Fenner, Hamburg, Germany, 2City Laboratory, Hamburg, Germany, 3Fen-Lab, Hamburg, Germany.
Tuesday, 2:00 p.m. - 4:30 p.m.	184. Resistance by Ribosome Alteration	1813. High-Level Ketolide-Resistant Streptococci	A. G. TAIT-KAMRADT1, R. R. REINERT2, A. AL-LAHHAM2, D. E. LOW3, J. A. SUTCLIFFE1;	1Pfizer Global Res. and Dev., Groton, CT, 2Natl. Reference Ctr. For Streptococci, Aachen, Germany, 3Mount Sinai Hosp., Toronto, ON, Canada.
Tuesday, 2:00 p.m. - 4:30 p.m.	185. Pediatric Infectious Diseases	1826. Short Course Antibiotic Therapy of Streptococcal Pharyngitis: Comparison of Clarithromycin with Amoxicillin/Clavulanate and Cefuroxime Axetil	D. ADAM1, H. SCHOLZ2, H. HAVERKAMP3, M. HELMERKING3;	1Dept. of Antimicrobial Therapy, Dr. v. Haunersches Children's Hosp., Univ. of Munich, Munich, Germany, 2Inst. for Infectiology, Microbiol. and Hygienics, Municipal Hosp. Buch, Berlin, Germany, 3Algora Clin. Res. Organization, Munich, Germany.
Tuesday, 3:00 p.m. - 4:30 p.m.	189. Meningitis	1856. Regulation of Caspases in Experimental Pneumococcal Meningitis	MATTHIAS H. P. V. MERING, T. KAMBACH, J. GERBER, U. MICHEL, S. BUNKOWSKI, R. NAU;	University Hospital of the Georg-August-University Goettingen, Goettingen, Germany.
Tuesday, 3:00 p.m. - 4:30 p.m.	189. Meningitis	1858. Combining Antiinflammatory and Antioxidative Therapy in Experimental Meningitis Had No Beneficial Effect on Mortality and Spatial Memory	J. GERBER, C. BOLLINGER, R. NAU;	Georg-August-University, Goettingen, Germany.
Tuesday, 3:00 p.m. - 4:30 p.m.	190. Antimicrobial Use and Resistance	1866. Clinafloxacin, Linezolid and Telithromycin Can Select for Resistant Bacteria in the Human Intestinal Microflora	C. EDLUND1, H. LODE2, C.E. NORD1;	1Karolinska Institute, Stockholm, Sweden, 2Hospital Zehlendorf/Heckeshorn, Berlin, Germany.
Tuesday, 3:00 p.m. - 4:30 p.m.	192. Herpesviruses	1885. Comparison of Two Different Real-Time PCR Assays and the COBAS Amplicor CMV Monitor for the Detection of Cytomegalovirus-DNA in Patients after Allogeneic Bone Marrow Transplantation	JUERGEN H. LOEFFLER, H. HEBART, E. SZENTGYOERGYI, H. EINSELE;	Medizinische Klinik, Tuebingen, Germany.
Tuesday, 3:00 p.m. - 4:30 p.m.	192. Herpesviruses	1885. Comparison of Two Different Real-Time PCR Assays and the COBAS Amplicor CMV Monitor for the Detection of Cytomegalovirus-DNA in Patients after Allogeneic Bone Marrow Transplantation	JUERGEN H. LOEFFLER, H. HEBART, E. SZENTGYOERGYI, H. EINSELE;	Medizinische Klinik, Tuebingen, Germany.
Tuesday, 3:00 p.m. - 4:30 p.m.	193. Antiretroviral Therapy I	1907. Enhancement of HIV-Specific Immune Response during Structured Treatment Interruptions (STIs) in Chronic Infection Depends on Baseline Viral Load	C. HOFFMANN1, W. MAYER2, E. WOLF1, M. SOVRIC1, E. GERSBACHER1, R. VON BAEHR2, F. W. TILLER3, E. JAEGEL-GUEDES1, H. JAEGER1, W. BIEGER3;	1KIS - Curatorium for Immunedeficiency, Munich, Germany, 2Alphagen GmbH, Munich, Germany, 3Immunological Laboratories, Munich, Germany.
Tuesday, 3:00 p.m. - 4:30 p.m.	193. Antiretroviral Therapy I	1910. Long-Term Effects of Treatment Interruptions: 18-Month Evaluation of a Controlled Trial in > 300 HIV+ Patients	E. WOLF1, E. GERSBACHER1, J. SCHARDT1, S. MUELLER1, C. HOFFMANN2, M. PROCACCIANTI3, F. MOSTHAF3, A. ULMER4, E. JAEGEL-GUEDES2, H. JAEGER2;	1MUC Research GmbH, Munich, Germany, 2KIS - Curatorium for Immunedeficiency, Munich, Germany, 3Private Practice, Karlsruhe, Germany, 4Private Practice, Stuttgart, Germany.
Tuesday, 3:00 p.m. - 4:30 p.m.	193. Antiretroviral Therapy I	1915. The Stability of the Viral Load in Subjects with Virological Failure who Remain on the Same HAART Regimen: The EuroSIDA Study	J. D. LUNDGREN1, A. COZZI-LEPRI2, V. MILLER3, B. LEDERGERBER4, S. VELLA5, J. WEBER6, J. N. BRUUN7, O. KIRK1, B. CLOTET8, A. PHILIPS2;	1EuroSIDA Coordinating Centre, Hvidovre, Denmark, 2Royal Free Hospital, London, United Kingdom, 3J W Goethe, Frankfurt, Germany, 4Univ Hosp, Zürich, Switzerland, 5Inst Superiore, Rome, Italy, 6St Mary's Hosp, London, United Kingdom, 7Ullevaal Hosp, Oslo, Norway, 8HUiGTiP, Barcelona, Spain.
Tuesday, 3:00 p.m. - 4:30 p.m.	194. Antiretroviral Therapy II	1925. Kaletra (lopinavir/ritonavir) and Efavirenz: 72 Week Safety/Efficacy Evaluation andPhenotypic/Genotypic Breakpoints in Multiple PI Experienced Patients	S. DANNER1, S. BRUN2, J. SYLTE2, J. ISAACSON2, A. LAZZARIN3, P. M. GIRARD4, J. ROCKSTROH5, S. BECKER6, G. PANTALEO7, F. BERGMANN8, N. CLUMECK9, D. HO10, R. TUBIANA11, G. CAROSI12, R. BERTZ2, A. HSU2, M. KING2, B. RICHARDS2, D. KEMPF2, E. SUN2;	1Academic Med. Ctr. Amsterdam, Amsterdam, Netherlands, 2Abbott Laboratories, Abbott Park, IL, 3Osp. S. Raffaele, Milano, Italy, 4H. Rothschild, Paris, France, 5Med. Klinik der Uni. Bonn, Bonn, Germany, 6Pacific Horizons Med. Grp., San Francisco, CA, 7H. de Beaumont, Lausanne, Switzerland, 8Charite Humboldt-U. Berlin, Berlin, Germany, 9CHU Saint-Pierre-Brussels, Brussels, Belgium, 10Aaron Diamond, New York, NY, 11H. Pitie-Salpetriere, Paris, France, 12U. of Brescia, Brescia, Italy.
Wednesday, 8:30 a.m. - 11:30 a.m.	212. Pneumococcal Vaccines	2038. Immunization of Mice with the Cell Wall-Associated Serine Protease PrtA of Streptococcus pneumoniae Protects against Invasive Pneumococcal Infection	I. AZEH1, R. NAU1, G. BETHE2, A. NEUHAUS2, A. WELLMER1, H. P. HEINZ2, G. ZYSK2;	1Neurology, Univ. Hosp., Goettingen, Germany, 2Med. Microbiol., Univ., Duesseldorf, Germany.
Wednesday, 8:30 a.m. - 11:00 a.m.	213. Bloodstream and Vascular Catheter Infections: Progress!	2044. Catheter-Related Bloodstream-Infection (CRBSI) in Neutropenic Cancer Patients Determined by Quantitative Blood Cultures (QBC), Differential Time to Positivity (DTP), and Molecular Epidemiologic Typing with PFGE	HARALD SEIFERT1, K. SEGGEWISS1, M. DECKER1, H. WISPLINGHOFF1, H. LOEVENICH2, O. CORNELY2, G. FÄTKENHEUER2;	1Institute of Medical Microbiology, Immunology and Hygiene, Cologne, Germany, 2Department for Internal Medicine, University of Cologne, Cologne, Germany.
Wednesday, 8:30 a.m. - 11:00 a.m.	215. Guidelines: Is the Juice Worth the Squeeze?	2063. A Decision Support System (DSS) for Antibiotic Treatment Improves Empirical Treatment and Reduces Costs	B. KRISTENSEN1, S. LARSEN2, H. C. SCHOENHEYDER1, L. LEIBOVICI3, M. PAUL3, U. FRANK4, S. ANDREASSEN2;	1Aalborg Hosp, Aalborg, Denmark, 2Aalborg Univ, Aalborg, Denmark, 3Rabin Med Ctr, Petah Tiqva, Israel, 4Freiburg Univ Hosp, Freiburg, Germany.
Wednesday, 8:30 a.m. - 10:00 a.m.	216. Pharmacodynamics of Antimicrobials I: In Vitro Models	2078. Influence of Sucrose and Human Serum on the Activity of Faropenem and Amoxicillin against Streptococcus pneumoniae	S. SCHUBERT1, U. ULLMANN1, A. DALHOFF2;	1Dept. Med. Microbiol., Univ. Hosp. Kiel, Kiel, Germany, 2Bayer AG, Wuppertal, Germany.
Wednesday, 8:30 a.m. - 10:00 a.m.	220. Novel Antibacterials III: Screens, Targets and Technologies	2124. Isoprenoid Biosynthesis as a Novel Antibacterial Target	A. JACOBI1, H. BAUM1, T. NAKANO2, R. R. ANNAND2, S. ANDERSON2, J. BREUNIG2, S. BOWES2, P. GOLDENBLATT2, S. S. ASHRAF3, H. GRØN3, P. HAMILTON3, D. J. CHRISTENSEN3, H. LOFERER1;	1GPC Biotech AG, Munich, Germany, 2GPC Biotech Inc., Cambridge, MA, 3Karo Bio USA, Durham, NC.
Wednesday, 8:30 a.m. - 10:00 a.m.	220. Novel Antibacterials III: Screens, Targets and Technologies	2132. Peptide Surrogate Ligands in Antimicrobial Drug Discovery for Targets of Unknown Function	S. S. ASHRAF1, H. GRØN1, E. ANDERSON1, A. MCNAMARA1, S. LLOYD1, D. DUFFIN1, A. JACOBI2, T. NAKANO3, R. R. ANNAND3, H. LOFERER2, D. J. CHRISTENSEN1, P. HAMILTON1;	1Karo Bio USA, Durham, NC, 2GPC Biotech AG, Munich, Germany, 3GPC Biotech Inc., Cambridge, MA.
Wednesday, 8:30 a.m. - 10:00 a.m.	221. Novel Antifungals and Antiparasitics	2144. PLD-118, a Novel Antifungal for Treatment of Yeast Infections: In Vivo Efficacy in Candida albicans Infection in Mice and Rats	W. SCHOENFELD1, J. MITTENDORF2, A. SCHMIDT2, U. GESCHKE2;	1PLIVA d.d., Research and Development, Zagreb, Croatia, 2Bayer AG, Pharma Research, Wuppertal, Germany.
Wednesday, 8:30 a.m. - 10:00 a.m.	221. Novel Antifungals and Antiparasitics	2146. PLD-118: Tolerability, Safety and Pharmacokinetics Following Single Oral Dose in Healthy Volunteers	K. ORESKOVIC1, A. BISCHOFF2, A. SCHROEDTER2, J. KNOELLER2, H. PAVICIC-STEDUL, A. AVDAGIC, M. DUMIC, Z. KRALJ,W. SCHOENFELD;	1PLIVA d.d., Research and Development, Zagreb, Croatia, 2FOCUS GmbH, Neuss, Germany.
Wednesday, 8:30 a.m. - 10:00 a.m.	221. Novel Antifungals and Antiparasitics	2163. Safety and Clinical Pharmacokinetics of DB289, a New Orally Bioavailable Dication	P. YERAMIAN1, M. KRUSE2, A. KECSKES2, J. ALLEN1, L. MCCHESNEY-HARRIS1, K. TRENDLER3, J. E. HALL4, R. TIDWELL4;	1Immtech Intl., Inc., Vernon Hills, IL, 2Parexel Inc., Berlin, Germany, 3Northwest Bioanalytical Inc., Salt Lake City, UT, 4Univ. of North Carolina, Chapel Hill, NC.
Wednesday, 10:00 a.m. - 11:30 a.m.	225. Sepsis	2216. The Protein Synthesis Inhibiting Clindamycin Improves Outcome in a Mouse Model of Staphylococcus aureus Sepsis Compared to the Cell Wall Active Ceftriaxone	I. AZEH1, J. GERBER1, M. WELLHAUSEN1, H. EIFFERT2, R. NAU1;	1Neurology, Univ. Hosp., Goettingen, Germany, 2Microbiol., Univ. Hosp., Goettingen
Wednesday, 10:00 a.m. - 11:30 a.m.	224. Antimicrobial Pharmacology	2196. Determination of the Excitatory Potency of Faropenem in the CNS by an In Vitro Model	G. SCHMUCK, E. VON KEUTZ, A. DALHOFF;	Bayer AG, Wuppertal, Germany.
Wednesday, 10:00 a.m. - 11:30 a.m.	224. Antimicrobial Pharmacology	2207. Chondrotoxicity of Ofloxacin Compared with BMS 284,756 in Juvenile Rats	S. F. FASSHEBER1, E. M. KAPPEL2, K. RIECKE2, U. RAHM2, M. SHAKIBAEI3, R. STAHLMANN2;	1Institute of Clinical Pharmacology and Toxicology, Berlin, Germany, 2INSTITUTE of Clinical Pharmacology and Toxicology, Berlin, Germany, 3Institute of Anatomy, Berlin, Germany.
Wednesday, 10:00 a.m. - 11:30 a.m.	225. Sepsis	2216. The Protein Synthesis Inhibiting Clindamycin Improves Outcome in a Mouse Model of Staphylococcus aureus Sepsis Compared to the Cell Wall Active Ceftriaxone	I. AZEH1, J. GERBER1, M. WELLHAUSEN1, H. EIFFERT2, R. NAU1;	1Neurology, Univ. Hosp., Goettingen, Germany, 2Microbiol., Univ. Hosp., Goettingen
Wednesday, 10:00 a.m. - 11:30 a.m.	227. Miscellaneous Resistance	2238. Occurrence of the Florfenicol Resistance Gene cfr in Staphylococci of Human and Animal Origin	S. SCHWARZ1, C. KEHRENBERG1, F.-J. SCHMITZ2;	1Inst. Animal Sci. and Animal Behaviour, Celle, Germany, 2Inst. Med. Microbiol. and Virol., Düsseldorf, Germany.
Wednesday, 10:00 a.m. - 11:30 a.m.	227. Miscellaneous Resistance	2239. Chromosomal Location of Florfenicol Resistance Genes in Escherichia coli	B. DOUBLET1, S. SCHWARZ2, G. FRECH2, S. BAUCHERON1, J.-L. MARTEL3, E. CHASLUS-DANCLA1, A. CLOECKAERT1;	1INRA, Nouzilly, France, 2Inst. Animal Sci. and Animal Behaviour, Celle, Germany, 3AFSSA, Lyon, France.
Wednesday, 10:00 a.m. - 11:30 a.m.	230. In Vitro Susceptibility: Miscellaneous	2264. Surveillance of Susceptibility Patterns in 1297 European and US Anaerobic and Micro-Aerophilic Isolates to Amoxicillin/Clavulanic Acid (A/C) and 5 Other Agents	L. M. KOETH1, M. R. BISCOTTI1, P. C. APPELBAUM2, L. J. DUBREUIL3, E. J. C. GOLDSTEIN4, A. C. RODLOFF5;	1Laboratory Specialists Inc, Cleveland, OH, 2Hershey Medical Center, Hershey, PA, 3University of Lille, Lille, France, 4RM Alden Research Foundation, Los Angeles, CA, 5University of Leipzig, Leipzig, Germany.